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4I am delighted to welcome this new report from
the National Advisory Committee on Drugs
(NACD) on the potential usefulness of Naloxone
as a treatment option for opiate misuse.
The NACD was set up in 2000 to address gaps 
in our knowledge of drug use in an Irish context.
A three-year research work programme was agreed
by Government and the results of this work – 
and other studies that the NACD are carrying out –
will significantly increase the amount of available
research in this difficult and complex area.
Drug misuse, particularly opiate misuse, remains
one of the major social problems facing Irish
society today and the Government will continue
to work in partnership with communities most
affected by the problem. Implementing the 100
actions in the National Drugs Strategy 2001 –
2008 and initiatives such as the Local and
Regional Drugs Task Forces remains a priority 
for Government.
The Strategy aims to broaden the range of
treatment approaches available to drug misusers.
In this context, it aims to have in place in each
Health Board area a range of treatment and
rehabilitation options as part of a planned
programme of progression for each drug misuser. 
I hope that through greater understanding of the
usefulness of Naloxone, this study will help to aid
the overall treatment of opiate users in this country.
Noel Ahern T.D.
Minister of State with responsibility for the
National Drug Strategy
Minister of State’s Foreword
5The NACD is required to advise Government about
a number of aspects of the drugs phenomena in
Ireland, notably the consequences of problem drug
taking. The ultimate consequence with some drugs,
for example heroin, is death, and problem drug
users have mortality rates 20-30 times greater than
normal. Surprisingly international experience
indicates that most deaths occur, not in naïve
experimenting drug users who cannot judge their
dose of drug, but in experienced drug users in their
late 20s and early 30s.
Methods to prevent such tragic premature deaths
are urgently required. These measures can include
advice to avoid using combinations of opiates
(heroin or methadone) with tranquillisers
(“benzos”) and alcohol which are particularly lethal.
Drug users who have become abstinent through a
‘detox’ also need to be counselled that if they slip
back into drug use, their ability to tolerate high
doses of a drug will have disappeared and that
using such doses could now result in an overdose.
One medical response to opiate overdoses is the
drug Naloxone which has been used for many
years in casualty and A&E Departments to reverse
the effects of opiate overdoses. As this review of
the drug, ably put together by Dr. Mary Teeling
and her team at St. James’s Hospital, points out,
speedier administration of Naloxone might have 
a role to play in reducing the death toll from drug
overdoses. The NACD hopes that this report will
help stimulate and inform discussions among 
those with responsibility for planning and delivery
of emergency services about the proper role 
for Naloxone in such services. The report also
describes the use of the drug in rapid opiate
withdrawal and in combination with Buprenorphine
as a maintenance treatment which was the subject
of an NACD report in 2002.
All in all Naloxone is a drug which has much 
to offer within our overall response to problem
drug taking and the NACD wishes, through this
technical report to highlight its potential.
Dr. Desmond Corrigan
Chairperson
NACD
Preface
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8Opiate dependency continues to be a cause 
of morbidity and premature mortality among 
the inhabitants of the EU. Although many
treatment modalities have been used, the
pharmacotherapeutic approach, using
methadone maintenance therapy, has proved
most beneficial to date and is the mainstay of
treatment in the Irish setting.
A systematic review was undertaken in order 
to evaluate the potential usefulness of naloxone
as a treatment option for opiate dependency. 
All available data were retrieved by means of a
comprehensive search of the published literature.
Contact was made with national and international
experts to evaluate the practical issues
associated with its use in the clinical setting.
Naloxone has been used in several treatment
settings in the management of opiate dependency.
It has been used for many years as an emergency
room treatment for the management of opiate
overdose. Evaluation of its use in this setting
suggests that it is associated with a low rate of
serious adverse effects but the data involved small
numbers of patients. Its administration by trained
ambulance staff in the pre-hospital setting resulted
in less hospital admissions but follow-up data of
the patients are lacking in many cases.
Although the availability of take-home naloxone
for use by friends and relatives of an opiate user
has been recommended by several workers,
there are no controlled trials evaluating such
usage. Furthermore records of use from pilot
studies are insufficient to undertake a benefit/
risk analysis of the use of naloxone in this setting.
There are many logistical issues that would need
to be dealt with before such a programme could
be implemented in practice. 
Naloxone has been used, with or without
naltrexone, to effect rapid opiate withdrawal.
Results of studies have shown that the withdrawal
occurs earlier and is more severe with use of
naloxone compared with α2-adrenergic agents
such as clonidine. However, it resolves more
quickly leading to a quicker transition to
maintenance antagonistic treatment. The long-
term benefits of rapid withdrawal have not been
compared with those from standard withdrawal
regimens. Data are insufficient to identify the
most appropriate dosage regimen.
A combination preparation of buprenorphine 
and naloxone (4:1 ratio) for sublingual use has
recently been developed. It has been shown 
to be effective as a maintenance treatment for
opiate dependence, while the presence of
naloxone reduces the risk of misuse of the
buprenorphine component. Data are insufficient
to identify the optimal treatment regimen. The
combination has been shown to be equipotent to
buprenorphine alone. Subutex® is authorised for
use in opiate dependence in Ireland, but there is
no combination of buprenorphine and naloxone
currently authorised.
This review has found data on the safety and
efficacy of naloxone in its many potential uses 
in the management of opiate dependency are
limited. However preliminary results suggest 
that it may be of use in these areas. Further
information on the feasibility of use as an
emergency treatment in the community setting
would be needed before any such programme
could be implemented.
Executive Summary
9Problem drug use, defined as injecting drug use
of long-duration/regular use of opiates, cocaine
and/or amphetamines, continues to be a problem
throughout the European Union (EU). A recent
capture recapture study of the prevalence of
opiate use in Ireland 2000-2001 (Kelly et al, 2003)
showed an overall prevalence of opiate use of
5.6/1,000 population. Males aged 25-34 years had
a higher national prevalence (13.7 and 14.7/1,000
pop for 2000 and 2001) compared with the
remaining males and females of all ages. Opiate-
related deaths are a significant cause of premature
death, especially in young adult males (Ward and
Barry, 2001).
In April 2001, the Irish Government approved 
the National Drugs Strategy, 2001-2008 entitled
“Building on Experience”. This strategy has
identified 7 overall aims including the
accessibility of treatment for people with drug
misuse problems, reduction of harm caused by
such drug use to individuals, families and
communities and reduction of risk behaviour
associated with drug misuse (Sinclair et al, 2001). 
Methadone maintenance is still the major form 
of substitution treatment in Ireland and this is
provided to persons who fulfil specific criteria of
admission. Although methadone maintenance
treatment is associated with reduced mortality
among opiate users (Caplehorn et al, 1994),
methadone overdose is also dangerous – a
recent study of opioid-related deaths in Dublin
during 1999 (Ward and Barry, 2001) showed that
45/84 (53.6%) deaths were related to methadone.
Diverted methadone accounted for the majority
of deaths involving methadone.
Buprenorphine has been used as a maintenance
treatment in some EU countries since 1996 and
was recently authorised for such use by the Irish
Medicines Board in Ireland. A review of the
usefulness of buprenorphine was undertaken
previously (Teeling et al, 2002), on behalf of the
NACD and this showed that buprenorphine
could be considered a useful treatment option 
in the management of opiate dependence with
an acceptable safety profile. 
Following on from this review the NACD has
commissioned a study evaluating the use of
naloxone as another pharmacotherapeutic
option. Naloxone is an opiate antagonist, which
has been used as an emergency treatment for
the management of opiate overdose in hospitals
for several decades. The expansion of the use of
naloxone to include its administration in the
community has been suggested in recent years
by many drug treatment workers in an effort to
reduce or prevent fatal opiate-related overdoses.
This review has been commissioned to evaluate
the potential usefulness of naloxone in the
overall management of opiate dependence
syndrome in the Irish setting.
Introduction
Chapter 1
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The aim of this review was to evaluate the
usefulness of naloxone as an intervention in the
management of Opiate Dependence Syndrome.
The objectives of the review were to:
1. Retrieve and systematically review all
published literature relating to the use of
naloxone in the management of opiate
dependence syndrome, in particular its use 
as an emergency treatment for overdose in
the emergency room and community setting.
2. Evaluate the practicalities of use of naloxone
in these potential treatment settings.
Aims and Objectives of the Review
Chapter 2
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Primary and review articles, abstracts and other
published information on naloxone were
identified using the following sources – 
 Medline, Pharmline, Micromedex, Iowa Drug
Information Service, (computerised indexing
and retrieval systems)
Review journals (such as Drugs) and reference
textbooks (Martindale 32nd edition,
“Pharmacological Basis of Therapeutics”
Goodman and Gilman 10th Edition) were also
searched for background pharmacology.
The National Documentation Centre’s electronic
library and specialist textbooks were searched for
relevant articles and publications.
The search terms used were as follows – opiate,
opioid, naloxone, opioid antagonist, naltrexone
addiction, therapeutic, withdrawal, detoxification,
emergency treatment, overdose, methadone and
heroin. These were employed separately and in
combination with one another. The reference lists
of relevant articles and reviews were examined
for further reports.
No time limit was put on the earliest date for
acceptability of data and studies were evaluated
from 1980 onwards. The data lock point for
inclusion in the review was the 15th December,
2002. Articles that became available after that
time were taken into account if they were 
judged to provide additional information, 
which might influence the outcome of the review.
Once identified, all papers were evaluated for
relevance to the review and were included in 
the assessment if considered relevant.
The data on usage of naloxone in different areas
of management of opiate dependence syndrome
were reviewed, in particular, its use as an
emergency treatment for opiate overdose, to
determine its usefulness in each clinical situation.
It was not possible to undertake formal meta
analysis in any of the areas of use, due to lack 
of suitable data. A meta analysis is a statistical
technique for combining the results of
independent studies, to present an objective 
and quantitative measure of effectiveness of an
intervention. It reduces the chances of Type II
errors by pooling the data across several smaller
studies and therefore increases the confidence
with which the efficacy of an intervention can be
assessed (Sutton et al, 1999; Chalmers and
Altman, 1995).
Finally, in order to identify the practicalities of 
use of naloxone in the various treatment settings,
information on use in clinical practice was
identified from the published literature. Where
possible, healthcare professionals, experienced 
in its use were identified in Ireland and abroad
and contacted for further specific data on the
advantages and disadvantages of such usage 
in clinical practice. Contact was made with the
Department of Health and Children to identify
possible medico-legal issues involved in the use
of naloxone as an emergency treatment.
Research Methodology of the Review
Chapter 3
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Naloxone
4.1 Introduction
Opioid antagonists have been involved in the
management of opiate dependent syndromes 
for many years. Opioid antagonists act by
competitively binding at opiate receptors
(Chamberlain and Klein, 1994) including mu,
kappa and stereo-specific binding sites in the
locus coeruleus of the brain. They are also
thought to reverse opiate-induced respiratory
depression by resensitising the respiratory centre
to carbon dioxide (Rawal et al, 1986).
They have been used to reverse opioid overdose
and more recently, they have been used in
combination with other pharmacological agents,
as part of managed withdrawal, abstinence and
maintenance programmes in opiate dependence.
4.2 Pharmacology
Naloxone is an N-alkyl derivative of oxymorphine.
Unlike other agents in the class, it has little or 
no agonist activity and therefore is a safe and
effective treatment for opiate-induced respiratory
depression (Chamberlain and Klein, 1994). It
binds most strongly to mu receptors but displays
antagonist activity at the other opioid receptors
as well. It is highly lipophilic so that distribution
to the brain is rapid.
Under ordinary circumstances, naloxone produces
few effects unless opioids with agonistic actions
have been administered previously – subcutaneous
naloxone at doses of up to 12mg produced no
discernible subjective effects in human volunteers
and 24mg only caused slight drowsiness. (Gutstein
and Akil, 2001). However, small doses (0.4 – 0.8mg)
given intramuscularly (IM) or intravenously (IV)
prevent or promptly reverse the effects of mu
receptor agonists. In patients with respiratory
depression, the respiratory rate increases within 
1 or 2 minutes. Duration of the antagonistic effects
depends on the dose and route of administration
(SPC, 2002) with IM injection producing a more
prolonged effect than IV doses. In general, clinical
efficacy for opioid antagonism lasts for 45-70
minutes, although longer effects have been
reported (Chamberlain and Klein, 1994). It has a
half life of approximately 60 minutes in adults. 
Antagonism of opioid effects by naloxone may
be accompanied by “overshoot” phenomena.
For example, respiratory rate, depressed by
opioids, becomes higher than the rate prior 
to depression after naloxone administration.
Rebound release of catecholamines may cause
hypertension, tachycardia and arrhythmias.
Pulmonary oedema has been reported with use
of naloxone (Gutstein and Akil, 2001). These
reactions have been reported rarely in clinical
usage (see chapter 5).
4.3 Pharmacokinetics 
Following oral administration it has poor
bioavailability (2%) due to extensive first pass
metabolism. Therefore, it is usually administered
via the parenteral route although endotracheal
and sublingual routes have also been used
successfully (Trujillo et al, 1998). Less than 1% of
the drug is excreted via the renal mechanism as
unchanged drug. It is extensively metabolised 
i.e. over 90% with a short elimination half-life in
the region of 60 minutes. The main metabolising
enzyme is glucuronyl transferase with
glucuronidation accounting for 60 – 70% of 
total metabolism. 
Potential pharmacokinetic interactions may occur
when co-administered with medications that are
extensively metabolised by the same enzyme
system. These medications are outlined above
(see section 4.3). Case reports also suggest an
interaction with the ACE inhibitor captopril,
reducing the anti-hypertensive effect via an
unknown mechanism. 
4.4 Summary
Naloxone is an opioid antagonist, with little or 
no agonist activity. It is not active orally because
of extensive first pass metabolism. Potential
pharmacokinetic interactions may occur when 
co-administered with medications that are
extensively metabolised via glucuronidation.
Overall, the propensity for clinically relevant
pharmacokinetic drug interactions is thought 
to be relatively low.
Pharmacology
Chapter 4
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5.1 Introduction
The use of the opioid antagonist naloxone in the
emergency management of overdose of heroin 
or other opioid agonists has been reported since
the early 1960s (Osterwalder, 1996). It has been
estimated that naloxone may be the most
frequently prescribed specific antidote for human
poisonings (Chamberlain and Klein, 1994). More
recently its use for rapid detoxification has been
reported and it has also been combined with
buprenorphine, a partial opioid agonist, for use 
as maintenance treatment, as an alternative to
methadone. This review focuses primarily on the
use of naloxone in the emergency management of
opiate overdose and refers briefly to its other uses.
5.2 The Management of Opiate
Overdose
5.2.1 Emergency Room Usage
One of the most serious consequences of opiate
use, in particular heroin use, is the risk of
overdose (Dietze et al, 2000). Although variably
defined, heroin overdose comprises a triad of
depressed respiration with or without cyanosis,
altered consciousness (up to and including death)
and pinpoint pupils (Seidler et al, 1996).
Although naloxone has been used for the
management of suspected opiate overdose for 
4 decades very few clinical studies have been
undertaken to evaluate its safety and efficacy in
this indication, possibly for ethical and logistical
reasons (Osterwalder, 1997). A prospective case
series of 538 overdose episodes (involving 485
subjects who had overdosed with heroin alone or
in combination with other substances) evaluated
the complications attributable to naloxone
administration in the emergency room setting
(Osterwalder, 1996). As this was an observational
study, the dosage regimens and routes of
administration used varied (range 0.1 – 2.8mg
administered either IV or IM or both). A total of
6/453 (1.3%) patients who received naloxone
suffered a serious adverse event within 10
minutes of administration (doses of 0.2 – 0.8mg).
These included pulmonary oedema (n = 1)
generalised convulsions (n = 3) violent behaviour
(n = 1) and asystole (n = 1). Although a causal
association was not established conclusively, the
author cited other cases of pulmonary oedema
and cardiovascular adverse reactions from the
literature and maintained that there was strong
evidence to support a causal link with naloxone.
He concluded that such a high incidence of
serious adverse events was unacceptable and he
recommended that naloxone be used cautiously
in the emergency room. This study did not report
on efficacy of treatment but it is interesting to
note that 85/538 (15.8%) cases responded to
assisted breathing using a bag-valve-mask
device, without the need for naloxone.
The cases in Osterwalder’s paper were
confounded by the presence of co-existing
disease – hyperthyroidism (n = 1), epilepsy 
(n = 1) – and/or use of other drugs such as
benzodiazepines, alcohol, cocaine, all of which
could have contributed to the reported adverse
events (Hsu et al, 1997). However, the adverse
event profile reported is in keeping with previous
reports (see chapter 4).
A double blind randomised study (Kaplan et al,
1999) compared naloxone (2mg IV) with
nalmefene a longer acting opiate antagonist
(1mg or 2mg IV). The study involved 171 patients
with suspected opiate overdose who were
evaluated for 4 hours post administration of the
test drug. Patients were divided equally among
the 3 treatment groups. Results showed no
differences between the groups, in terms of
efficacy – all patients showed a rise in respiratory
rate by 5 minutes post injection and improved
scores on the neurobehavioral assessment scale
(NAS) – and no serious adverse reactions were
reported. The study had many methodological
flaws which reduced its power to detect
meaningful differences, however, the results
supported the efficacy of naloxone as a
treatment for suspected opiate overdose 
in the emergency room setting.
Summary
Naloxone has been used as an emergency room
treatment for suspected opiate overdose for
many years. However, there are few published
controlled trials in this setting. Cases of
convulsions, cardiovascular problems and
Review of Clinical Usage with Naloxone
Chapter 5
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pulmonary oedema have been reported rarely
with use. These may be due to occurrence of
overshoot phenomena due to the antagonism of
opioid effects by naloxone (see Chapter 4) or due
to pre-existing disease and/or concomitant use
of other drugs of abuse by the patient.
5.2.2 Use in the Community –
Ambulance Staff
The rates of fatal opiate overdose in much of the
developed world, including USA, Europe and
Australia, have risen in recent years (Darke and
Ross, 2000). It has been shown that death, due to
heroin overdose, occurs up to 3 hours after the
injection in up to 50% cases and the majority of
overdoses, including fatal ones, take place in the
company of others (Lenton and Hargreaves,
2000a). Therefore there is much interest in finding
ways to reduce or prevent fatal overdoses in the
community.
Data relating to use of naloxone prior to hospital
admission consists of a series of observational
studies as no controlled trials have been carried
out in this area. Yealy et al (1990) presented a
case series of 853 patients who had been treated
by paramedics with naloxone in the pre-hospital
situation for “blurred consciousness”, thought to
be due to opiate overdose. Five incidents (0.6%)
occurred, including generalised convulsions 
(n = 1), vomiting (n = 2) and one serious case
each of hypotonia and hypertonia. The authors
concluded that naloxone was safe for use in the
management of opiate overdose. However, since
only 60 patients were definitively diagnosed as
opiate overdose the significance of these results
in terms of proving safety of use of naloxone in
this indication has been called into question
(Osterwalder, 1996).
A survey from Vienna (Seidler et al, 1996)
reviewed the records of 77 subjects who were
treated for 83 emergencies (suspected opiate
overdose) in one of 4 hospitals over a 4-month
period. Naloxone was administered by
ambulance staff in 53/75 cases transported to
hospital – 16 received 0.4mg ; 21 received 0.8mg
and 16 received 3 or more ampoules of 0.4mg.
Four of these patients became agitated after
naloxone (thought to be due to withdrawal
reaction). No further naloxone was given in
hospital to 47 (63%) of subjects transported via
ambulance and only 9 (12%) received naloxone
for the first time in the emergency room.
A total of 47 patients discharged themselves after
an average stay of 5.7 hours, of whom 20 left
within the first 3 hours after admission. None of
the subjects needed readmission, further pre-
hospital treatment or died due to overdose
within 48 hours after leaving hospital. The authors
estimate that without pre-hospital administration
of naloxone, the clinical condition of at least 40
of these subjects would have required intubation
and admission to intensive care.
Sporer et al (1996) reviewed the use of naloxone
by paramedics in a pre-hospital setting during
1993 in an area of Los Angeles known for a high
prevalence of intravenous drug use.
Administration occurred as part of the Advanced
Life Support Emergency System and naloxone
was administered to patients according to strict
criteria. At least 3 of the following were required
– respiratory rate < 6/minute, pinpoint pupils,
evidence of intravenous drug use, Glasgow
Coma Scale < 12, or cyanosis.
A total of 726 patients were identified with a
diagnosis of suspected overdose, most of whom
(609 or 85%) had an initial pulse and blood
pressure. Most (94%) of this group responded to
naloxone – 487 (80%) received naloxone IM and
122 (20%) received the drug IV with or without
bag-valve-mask ventilation. Of the remainder, 
101 (14%) had obvious signs of death and 16
(2.2%) were in cardiopulmonary arrest but did not
survive. Of 443 patients transported to hospital,
12 were admitted – 4 with non-cardiogenic
pulmonary oedema, 2 with pneumonia, 2 with
other infections, 2 with persistent respiratory
depression and 2 with persistent alteration in
mental status. The authors noted that hypoxia 
was evident upon arrival to the emergency room
in those with pulmonary oedema. The study
concluded that use of naloxone in the pre
hospital setting, together with assisted ventilation
via the bag-valve-mask system was effective in 
this patient population and that serious adverse
events were evident from early on after treatment.
Finally, a prospective observational study was
undertaken by the ambulance service in British
Columbia, Vancouver (Wanger et al, 1998) to
evaluate whether naloxone (0.4mg) administered
IV would have a more rapid therapeutic onset
compared with subcutaneous administration of
naloxone (0.8mg). Results showed no difference
in interval from crew arrival to improvement of
15
respiratory rate to ≥ 10 breaths per minute (9.3+/-
4.2min versus 9.6+/-4.58min respectively). Mean
duration of bag-valve-mask ventilation was similar
for both groups (approximately 8 + 9 minutes).
The authors concluded that the slower rate of
absorption from the subcutaneous route was
offset by the delay in establishing IV access, 
thus resulting in equal efficacy for both routes.
Summary
Reports are available on the use of naloxone 
by ambulance personnel from various centres in
Europe and North America for the management
of suspected opiate overdose. It is important 
to note that the staff involved appeared to 
be trained in emergency procedures such as
diagnosis and initial management of suspected
opiate overdose (including administration of
therapeutic agents using IV, IM and subcutaneous
routes). Doses were titrated by these personnel
to achieve adequate response. The average dose
was <1mg (although doses up to 2mg were
administered in some cases). Results showed that
such usage was effective in terms of reversing the
effects of opiate overdose and reducing the need
for hospital admission. Adverse events occurred
rarely and were usually evident from initial arrival
in the emergency room.
The reports do not mention the occurrence of
delayed onset problems as a result of patients
opting not to travel to hospital post administration
of naloxone although several patients in each
study did not go to hospital for observation.
However one report (Seidler et al, 1996) did
mention that the hospital had a contingency 
plan in place in case a patient with a suspected
overdose of methadone or oral ingestion of
opiates chose not to stay for an optimal period 
of observation.
Available evidence suggests that pre-hospital
administration of naloxone by paramedics/
ambulance personnel may be beneficial in
patients with suspected opiate overdoses.
Administration to patients with loss of
consciousness not due to opiate overdose has
shown no benefit. Therefore relevant personnel
will require adequate paramedical training, 
both in diagnosis of suspected opiate overdose
and in parenteral administration techniques.
The Prehospital Emergency Care Council was
established in Ireland in 1999 and is currently
working on protocols for training of ambulance
staff as “advanced emergency technicians”.
Parenteral drugs are not administered by
ambulance staff at present, although most
ambulances carry emergency drugs. Naloxone is
not on the advisory list but it may be carried in some
ambulances (Kenna, personal communication).
5.2.3 Use in the Community – 
Peer Administration
Drug treatment workers in the UK and Australia
have promoted the idea of take-home naloxone
for heroin users for use by their family or friends
(so called peer administration) in order to prevent
or reduce fatal opiate overdoses. (Strang et al,
1999b; Lenton and Hargreaves, 2000a). No
controlled trials have been carried out to evaluate
the safety and efficacy of use of naloxone in this
indication but reports of initial usage are available
from the USA, UK, Germany and Jersey.
Dettmer et al, (2001) reported on 2 pilot projects.
From January 1999, opiate users in Berlin were
given naloxone to take home (2x 0.4mg ampoules
plus needles and syringes) and were offered
training in resuscitation . After 16 months, 124
users had received naloxone and resuscitation
training. Of 40 who reported back, 22 had used
naloxone for 29 overdoses. Dose and route of
administration varied although the commonest
dose administered was one ampoule. In 10
instances, naloxone provoked sudden withdrawal
but no other side effects were reported. An
ambulance was called for 9 cases but all 29
people were reported to have recovered. The
report states that administration was judged
appropriate in 26 (90%) cases, but it is not clear
how this conclusion was reached. The same report
referred to a similar project in Jersey, which began
in October 1998, where users were provided with
a prefilled injection pack of 0.8mg naloxone,
along with instructions on its use and basic
resuscitation techniques. Five instances of
naloxone use (out of 101 distributions) were
reported with no adverse events other than
withdrawal symptoms being recorded.
This report has been severely criticised as
“seriously flawed research” (Mountain, 2001)
because of its poor response rate (<35%) leading
to probable selection bias and because of the
lack of methodological information supplied to
support the validity of the results. Moreover, the
coroner’s figures for drug-related deaths in Jersey
supplied by Blackwood (2001) showed no change
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in the death rate during the period that the pilot
study was taking place.
The experience of use of take-home naloxone 
in Chicago was outlined in a recently published
letter (Bigg, 2002). To date over 550 active 
opiate injectors have been educated in 
the management of overdoses including
administration of naloxone IM. Reports of 52 
uses of naloxone have been received, all of which
were said to have been “successful”. (No further
details given) This report noted, however, that 
the experience had been unpleasant for both 
the overdose individuals and the administrator
resulting in a reluctance to repeat the incident. It
is assumed that this was due to the development
of withdrawal in the recipient but the report is
sparse on details of the individuals’ condition
pre-naloxone administration, use of concomitant
drugs, type of resuscitation used or whether an
ambulance had been called. Strang (2001)
reported that take-home naloxone has been
made available in some of the addiction
treatment services in South London since 2001,
but there are no reports of the outcome of this
availability to date.
In addition to these case reports it is understood
that naloxone has been made available to heroin
users as part of a training course on overdose
management and prevention by the San Francisco
Needle Exchange Unit (Darke and Hall, 1997). This
is reported to be similar to the Chicago system
but no results have been published. Italy made
naloxone available over the counter in pharmacies
for drug users in the 1990s but there are no
published reports of how this has affected opiate
overdose rates.
Summary
There is no information from controlled trials on
the safety and efficacy of peer administration of
naloxone in the prevention of opiate overdose.
Anecdotal reports of use in various centres are
available (involving <100 usages) but there is
insufficient information from these to evaluate
whether such usage has prevented fatalities 
from opioid overdose. It is noted that naloxone
distribution to opiate users has only taken 
place in conjunction with first aid training in
resuscitation, although the nature of the training
given is not clear in all cases.
Opiate overdose is a major cause of mortality 
in young males – the average annual mortality
rate among regular heroin injectors is 2%, a rate
6 – 20 times that for non-drug-using age peers,
half of which is attributable to overdose (Sporer,
1999). Therefore any treatment or intervention,
which could reduce these figures would have
considerable benefits to society. Since data from
controlled trials are not available to determine
whether naloxone is safe and effective when
administered by friends or relatives in the
community, potential benefits and problems 
with such usage in clinical practice will now be
considered.
5.2.4 Potential Benefits of 
Take-Home Naloxone
Opiate overdose is a common cause of
premature death in heroin users (Strang et al,
1996). Naloxone has been shown to be an
effective antidote and when used appropriately in
conjunction with basic resuscitation intervention
could prevent or reduce fatalities from overdose.
One of the main reasons put forward for the
provision of take-home naloxone for peer
administration is the fact that most overdoses occur
in the presence of others in the community, thereby
allowing for the possibility of peer administration of
naloxone (McGregor et al, 1998). Moreover despite
the fact that death, due to an opiate overdose may
not occur for 1-3 hours post intake of the opiate,
repeated studies have reported a reluctance on the
part of witnesses to call an ambulance (McGregor
et al, 1998; Darke et al, 1996a; Zador et al, 1996).
Therefore, peer administration of naloxone in the
early stages of overdose could reverse the effects 
of the opiate and reduce mortality.
Another potential benefit of take-home naloxone
is that it would be provided in the context of 
a first aid training programme in resuscitation.
This would make opiate users more aware of 
the risks of overdose and would enable them 
to give assistance if they witnessed an overdose.
The training programme could include education
regarding overdose risks, such as concomitant
use of alcohol, polydrug use or the risks of
solitary injecting (Darke et al, 1996b). Studies
have consistently shown that a longer history of
heroin use, greater heroin dependence and
higher levels of alcohol consumption are all risk
factors for overdose (Hall, 1999). All of these
areas could be specifically covered in a training
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programme. In addition, discharge from prison
may be a risk factor for overdose. A review of 
HIV positive injecting drug users who had spent
time in prison (n = 238) in Edinburgh showed an
increased risk of overdose after release (Seaman
et al, 1998). The risk of death from overdose for
the group during the first 2 weeks after release
from prison was 8 times higher than during the
next 10 weeks after release, probably due to a
decrease in tolerance to drugs as a result of less
frequent/lower drug injecting in prison.
Retention in methadone maintenance
programmes has been shown to reduce risk of
overdose (Caplehorn et al, 1994) and therefore 
it might be argued that if naloxone is only
administered as part of a training programme,
then those most at risk might not be reached 
as they would not be in regular contact with a
treatment centre. The San Francisco Needle
Exchange has organised such training courses 
for injecting drug users in its area since mid 1999.
This programme has used “underground”
sources to reach users (Lenton and Hargreaves,
2000b). A similar system has been in place in
Chicago for some time and it is reported that this
programme has encouraged hard-to-reach users
into making contact with the service (Lenton and
Hargreaves 2000b). Unfortunately no published
reports are available from the San Francisco
project and to date only outline information on
the Chicago project is available (Bigg, 2000;
section 5.2.3 above).
Naloxone has no abuse potential and as a result
should have no black market value. Therefore, 
its distribution to users for the purpose of peer
administration should not worsen the illicit drugs
trade. Some workers (Ashworth and Kidd, 2001)
have suggested that opioid antagonists could be
used as weapons against other drug users but
there have been no formal reports of this
happening.
5.2.5 Potential Problems with 
Take-Home Naloxone
Serious concerns have been raised by some
workers (Osterwalder, 1996; section 5.2.1 above)
about the safety of use of naloxone in this patient
population in general. Moreover, there have been
anecdotal reports (Gaddis and Watson, 1992) of
violent behaviour after naloxone administration,
requiring IV sedation. Naloxone has been used as
an emergency treatment in hospital settings for
many years, serious adverse events are predictable
and have been reported rarely. However, the
potential for serious adverse reactions would 
need to be included in a training programme.
There is concern that the availability of naloxone
in the community might interfere with other
harm reduction strategies, in particular the need
to call an ambulance (Lenton and Hargreaves,
2000a). This could increase the risk of fatal
overdose, especially if methadone or high doses
of opiates have been taken as naloxone has 
a short half life (60-90 minutes). Also, in most
cases of fatal overdose other drugs such as
benzodiazepines, other CNS active drugs and
alcohol will be found. Zador et al, (1996)
reported that 2 or more drugs were detected 
in 71% of 152 fatal heroin overdoses and alcohol
was detected in 45%. The short-acting nature 
of naloxone has recently been highlighted to
prescribers by the UK Committee on the Safety
of Medicines (CSM, 1997). The Committee
issued a recommendation that naloxone IV
infusion should be used in situations where a
longer-acting opioid is known or suspected to 
be the cause of the symptoms. However, results
from surveys undertaken in Australia (where
naloxone is not currently available for peer
administration) have shown that witnesses are
slow to call an ambulance – in only 17% of
overdose cases did the witness initially call an
ambulance (Darke et al, 1996a). These findings
have been repeated in other Australian studies
(Zador et al, 1996; Mc Gregor et al, 1998). 
Most cited fear of police involvement as the
impediment. Therefore the availability of
naloxone may not result in less calls for
ambulance help as it would only be made
available in conjunction with a basic first aid
training programme which would include the
importance of calling the ambulance service.
Most recently, Strang et al, (2000) interviewed 115
patients attending a methadone clinic in South
London about overdose experiences. Almost all
had witnessed overdoses (on an average of 6
occasions each). Most reported taking some action
and an ambulance had been called in 44% of
cases. This group expressed a willingness to learn
more about resuscitation techniques, including use
of naloxone and stated that fear of police
surveillance would not stop them from helping
someone who had overdosed (including calling an
ambulance). The differences in attitudes between
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UK and Australian users may be due to different
police policies in the different jurisdictions.
However, the impact of the availability of naloxone
on other harm reduction strategies can only be
definitively answered by way of a controlled trial
(Lenton and Hargreaves, 2000a).
Another concern which has been raised is that
administration of naloxone to heroin users would
encourage risky heroin and other drug use. This
is thought unlikely to happen as heroin is still
expensive in many jurisdictions and such usage
would be regarded as wasteful (Darke and Hall,
1997). Furthermore naloxone causes acute
withdrawal symptoms in many recipients which
make the experience unpleasant (Bigg, 2002).
Similar concerns were raised about the provision
of clean needles and syringes to users in the past
but these fears have not been borne out by the
evidence (Lenton and Hargreaves, 2000b). Since
naloxone would be provided in conjunction with
first aid training, it is likely that this information
would increase the recipients’ awareness of the
dangers of overdose rather than encourage use
of naloxone in a risky manner (Darke and Hall,
1997). However, qualitative research carried out
by Strang et al, (1999) showed that 19/142 (13%)
injecting drug users considered the distribution
of naloxone to be a “bad idea” and 9/142 (6%)
felt that it might increase their heroin use. Once
again, this question can only be definitively
answered by a controlled trial.
Another potential obstacle to the provision of
naloxone may be its cost and the short shelf life
for some presentations. In order for the scheme to
be effective all users attending the clinics would
need to be supplied with naloxone. Results from
the pilot projects (outlined above) to date have
reported minimal usage therefore, it is presumed
that most of the naloxone will not be used before
its expiry date. This also raises logistical problems
in that post-expired naloxone will need to be
replaced. Some workers have suggested that users
might be prepared to pay for a supply of naloxone
(Darke and Hall, 1997). This aspect of provision of
take-home naloxone would need to be dealt with
before any scheme could take place.
A major obstacle to supply of take-home
naloxone in many jurisdictions is its legal status.
Naloxone is a prescription only medicine and
therefore should only be prescribed by a
physician for a specific patient. If an adverse
event or fatality were to occur as a result of peer
administration, this could result in legal action
against the participants, including prescriber, the
person and/or institution which dispensed the
naloxone or the person who administered the
dose (Lenton and Hargreaves, 2000b). A review of
the legal aspects of providing naloxone to heroin
users in the USA was recently undertaken (Burris
et al, 2001). This concluded that since naloxone 
is the drug of choice for heroin overdose the
physician’s decision to prescribe would be seen
as reasonable and not negligent, assuming that
the patient was at risk of a fatal overdose and
was properly instructed in the administration 
and risk of use of naloxone.
In Ireland, naloxone is a Schedule IA drug 
i.e. requiring prescription for dispensing.
Distribution of naloxone to opiate users for peer
administration may be covered by the “carer
principle” i.e. where a lay person is taking care 
of a patient, he/she may administer a medicine,
given to the patient, on the patient’s behalf
(McGuinn, personal communication). However, 
a formal legal opinion would be required to
clarify the legal responsibilities of all participants
involved in the implementation of take-home
naloxone (See section 5.2.7).
A recent review of the strategies for preventing
heroin overdose (Sporer, 2003) published after
the data lock point, has discussed peer
administration of naloxone and has reiterated
many of the issues already highlighted in this
section. This review recommended that any
programme for take-home naloxone should
involve education on a) the identification and
management of overdose, including rescue
breathing b) the importance of contacting
emergency medical services and the need for
hospital evaluation after an overdose in order to
prevent/treat complications of both the drug(s) of
overdose and also naloxone and c) the
administration of naloxone and the need to use 
a sterile needle, if the naloxone is not in a
prefilled syringe. Because of the short half-life of
naloxone, it recommended that enough naloxone
for at least 2 doses should be provided. It stated
that evaluation of all potential problem areas
should be incorporated into any programme
established in this area.
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5.2.6 Future Initiatives in 
Take-Home Naloxone
Although many experts from Australia and the 
UK have been campaigning for a controlled 
trial to evaluate the benefit/risk of take-home
naloxone, no formal study has been undertaken
to date. Moreover, review of clinical trials
registers (www.controlled-trials.com;
www.clinicaltrials.gov) has not identified 
ongoing studies in this area.
It is noted in a personal communication from
Simon Lenton, National Drug Research Institute,
Curtin University, Perth, Australia, that his
research group has received approval in principle
from the relevant state agency to undertake a
multi-centre controlled trial (in several Australian
jurisdictions). The aim of such a trial would be 
to identify whether the addition of naloxone 
to the best available alternative (comprehensive
first aid training) would produce better or worse
outcomes than the first aid training alone. It is
unlikely that the trial will commence before mid
2003 as there are still many logistical problems 
to be addressed. Nevertheless, the undertaking
of a properly designed controlled trial would be
extremely useful in evaluating the benefit/risk of
the availability of naloxone in the community
setting for peer administration.
The 2002 Annual Report from the European
Monitoring Centre for Drugs and Drug Addiction
(EMCDDA) noted that between 7000 and 8000
deaths, due to accidental or intentional
overdose, were recorded during 2000 in the 
EU and Norway. Belgium, Germany, Finland,
Norway and the UK are reported to have
instituted programmes for the prevention of
overdoses. These include training of drug users
to protect against overdosing and to better
manage overdoses they witness. In addition,
programmes are said to include training in basic
resuscitation techniques, use of naloxone and
development of specific prevention information
materials (EMCDDA, 2002). Although no further
details on these initiatives are available, it is
hoped that information on their outcome will 
be available in the near future.
Therefore, despite problems outlined above 
(see section 5.2.5) it appears that take-home
naloxone is being supplied to opiate users in
some countries. Additionally, it seems likely that 
a controlled trial will be undertaken in Australia
within the next year. These initiatives should help
define what role, if any, naloxone use has in a
community setting for peer administration.
5.2.7 The Practicality of Take-Home
Naloxone in the Irish Setting
Official Irish statistics of drug-related deaths 
from the General Mortality Register (GMR) are
compiled routinely by the Central Statistics
Office. Data from the GMR show that drug-
related deaths increased from 43 in 1995 to 81 in
1997 (Sinclair et al, 2001). In 1998 an amendment
was made to the information recorded in the
case of a sudden death and the figure rose to 97.
Provisional figures for 1999 and 2000 showed a
levelling off at 85 and 89 respectively. The vast
majority of deaths each year were in Dublin and 
it is known that intravenous heroin use in Ireland
occurs primarily in the greater Dublin Area 
(Ward and Barry, 2001).
A retrospective review of coroners’ files for Dublin
City and County identified 84 Opiate-related
deaths in the region during 1999 (Ward and Barry,
2001). Toxicological analysis had been performed
on 82 victims of which 73 (87%) had identified 
use of 2 or more drugs. A total of 45 (53.6%) of
the deaths were associated with methadone use.
It is interesting to note that since methadone 
can only be dispensed to people on the Central
Methadone Treatment List (since Oct. 1998), this
finding implies diversion of methadone as not all
of the cases who had taken methadone were on
this treatment list.
The findings of this study are important for two
reasons. Firstly, they suggest that the overall
opiate-related death rate in Ireland is greater
than the GMR figures would suggest. Since these
deaths occurred in predominantly young males
(mean age 30.3 years) this represents a major
cause of premature death, most of which should
be preventable. Secondly, they show that if a
strategy is to be introduced to reduce opiate-
related death from overdose, the possibility of
polydrug use and use of methadone, a long
acting opiate must be borne in mind. The
findings underline the importance of ensuring
that naloxone distribution should be only one
aspect of a training programme, comprising 
1) education on the risks of polydrug use,
concomitant alcohol and solitary injection. 
2) the need to call an ambulance and 3) basic
resuscitation techniques.
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If a decision were taken to establish a take-home
naloxone programme, despite the availability 
of supporting data from clinical trials, several
important areas would need to be clarified.
Firstly, the legal basis and potential liabilities 
of the parties concerned must be satisfactorily
addressed (see section 5.2.5) before a
programme can be initiated.
Secondly, it must be decided where the
programme will be based – should it be 
made available in all drug treatment centres/
GP surgeries involved in managed opiate
dependence, or should it be run through other
outlets. The Naloxone programmes in Chicago
and San Francisco (see section 5.2.3 above) are
run through needle exchange units and therefore
aim to target those currently injecting opiates.
There is a limited number of needle exchange
units in Ireland at present, therefore, it is unlikely
that they would have contact with all of the
potential clients of such a scheme. The location of
a programme would be important in determining
whether or not it would be successful, therefore
careful planning would need to be undertaken in
this regard.
The capacity of drug treatment centres to
implement take-home naloxone as part of a
comprehensive training programme would also
need to be evaluated. A recent survey of drug
treatment centres in the UK (Winstock et al, 2000)
reported that although 291/345 (84%) agencies
had staff trained in resuscitation, only 20% had
access to either oxygen or naloxone. Yet 21% of
the agencies had experienced an overdose on-
site at some time. The authors recommended
that all agencies should provide basic
resuscitation facilities and client training in the
management of overdose.
Comprehensive information on the availability of
naloxone or the training level of the drug workers
in Irish treatment centres is not readily available.
Most centres that dispense methadone have a
doctor and nurse on site or on call (as at
weekends) but the level of resuscitation facilities
and the availability of naloxone are unknown.
Most GP surgeries would have basic resuscitation
equipment but would not hold naloxone supplies
(Delargy, personal communication). If a training
programme on resuscitation and take-home
naloxone were to be made available at all
treatment centres, the staff would need to be
adequately trained to provide such training. This
would have time and resource implications for
these clinics.
The establishment of such a programme would
also require ongoing evaluation, both in terms 
of outcome of the programme (usefulness of
naloxone etc) and dispensing and monitoring 
of supplies to ensure that they are in-date. Once
more, this would require input from the staff with
resulting resource implications.
Finally, the feasibility of enrolling current IV users
in a training programme must also be assessed.
Although the reports outlined in section 5.2.3
(above) state that naloxone was administered in
conjunction with training, details on how this was
achieved were lacking. Results from a pilot study
involving 9 opiate users in Glasgow (Graham et
al, 2001) showed that all participants were able 
to perform basic resuscitation techniques after 
a training programme. Details on the type of
training were not supplied. Although these
results are encouraging it must be noted that all
9 participants volunteered to undertake training.
It would be important to ensure that potential
recipients (and/or their families) would only be
allowed into the programme if they agreed to
complete such training.
Dr. Michael Ryan is a Dublin-based doctor who is
involved in the management of drug users. He has
a particular interest in the use of naloxone in the
emergency management of opiate overdose to
prevent fatalities. He is involved with the DOORS
(Dublin Opiate Overdose Reduction Strategy)
group. This group (made up of professionals
working in the area of drug dependence) would
like a system for naloxone distribution for peer
administration to be instituted in Ireland and has
recently drawn up an outline proposal for such 
a scheme (Ryan, personal communication). In 
Dr. Ryan’s opinion, such a system should only be
implemented as part of a comprehensive training
programme and initially it could be limited to
users and their families.
Summary
Fatal opiate overdose is a major cause of
premature mortality, especially in males.
Naloxone has been used as an antidote for many
years in the emergency room. Many workers have
recommended that take-home naloxone should
be given to users for peer administration in case
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of opiate overdose. Although there are
preliminary reports of such use from several areas
in the UK and USA, there are no data from clinical
trials to evaluate whether use of naloxone in this
circumstance has any advantage over education
and training in basic resuscitation techniques
alone. It is noted that several EU countries
appear to have implemented overdose reduction
strategies in recent times, some of which may
involve use of take-home naloxone and it is
hoped that outcome information from these
initiatives will be made available. Such
information would be useful in determining
whether take-home naloxone has resulted in a
reduction in fatal overdoses in these countries.
Furthermore, a controlled trial may be
undertaken in Australia in the near future but 
the results may not be available for some time.
Apart from the lack of clinical trials data to
support the safety and efficacy of naloxone in this
indication there are many logistical issues that
need to be evaluated before implementing a
take-home naloxone programme. The legal
consequences for all parties would need to be
defined. A comprehensive training programme
(including education on risky opiate use, the
need to seek ambulance assistance, even with
naloxone usage, as well as basic first aid training)
would need to be provided in conjunction with
the supply of naloxone. This would have major
resource implications, especially if the
programme were to be implemented nationally.
Ongoing monitoring of the programme would be
necessary to evaluate outcome and to ensure an
adequate supply of in-date stock. This would also
have major resource implications.
Finally, it is important that any programme 
would target those most at risk. Since retention 
in a methadone maintenance programme has
been shown to reduce fatal opiate overdose
(Caplehorn et al, 1994), it may be difficult to
target at-risk groups i.e. those who don’t attend
clinics. An appropriate method of enrolling this
group would need to be implemented.
5.3 Use in Managed Withdrawal
Traditionally, managed opiate withdrawal has
involved the use of reducing doses of methadone
or α2-adrenergic agonists (O’Brien, 1997). More
recently, techniques known as rapid opioid
detoxification (RD) and ultra rapid opioid
detoxification (URD) have been developed. 
These are designed to shorten detoxification 
by precipitating withdrawal, using opioid
antagonists, including naloxone (O’Connor 
and Kosten, 1998). The rationale is that patients
complete detoxification rapidly (1 – 5 days)
enabling naltrexone maintenance (with
counselling) to occur more quickly, thereby
preventing relapse. RD usually involves
administration of naloxone and/or naltrexone in
association with other agents that will ameliorate
the signs and symptoms of withdrawal (such as
clonidine, lofexidine or buprenorphine) according
to a protocol typically lasting 5 or more days.
URD involves rapid IV administration of naloxone
(minutes – few hours) to precipitate withdrawal
using sedation or general anaesthesia, to help
counteract the symptoms.
O’Connor and Kosten (1998) undertook a
systematic review of RD and URD published trials.
A total of 5 studies using naloxone for RD were
identified but these involved only 118 patients
whose clinical spectrum varied. Studies were
generally not randomised or controlled. In
addition, there was no consistency in 1) dosage
regimen of naloxone used or whether it was used
with or without naltrexone, 2) duration of treatment
or 3) concomitant medications used. Although
results generally recorded high completion rates,
these were hard to interpret because most studies
only commented on the period of detoxification,
with no period of follow-up thereafter. Therefore it
was not possible to evaluate the effectiveness of
RD using naloxone or to identify the appropriate
dosage regimen (including concomitant drugs) or
duration of treatment.
Most of the URD studies (n = 9 in total) identified
came from one centre and each had enrolled
small numbers of patients. One large study was
identified (Seoane et al, 1997) which administered
IV naloxone 0.06-0.08mg/kg via rapid infusion 
(5-10 minutes) to 300 heroin users, followed by
oral naltrexone 50mg/day. Patients were
randomised to receive either light or heavy
sedation. Results showed that all patients were
successfully detoxified and 279 (93%) remained
abstinent at the end of one month. However,
details on the method of follow-up are sparse. 
In terms of safety, 4 in the heavy sedation group
and 2 in the light sedation group required
intubation and one patient developed aspiration
pneumonia, which responded to antibiotic
treatment.
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The reviewers (O’Connor and Kosten 1998)
suggest that data on the safety and efficacy of
RD and URD are still limited, therefore further
data from properly designed trials, with longer
term outcome evaluation are needed to fully
elucidate the place of RD and URD in the overall
management of opiate dependence.
Gowing et al (2002) undertook a systematic
review of opioid antagonists in the management
of opiate withdrawal. They noted that there was
great variability in the 10 studies that were
included in the review in terms of
a. Use of naloxone or naltrexone or both in
combination
b. Type of dosage regimens
c. Concomitant use of medications to ameliorate
withdrawal (such as clonidine, lofexidine or
buprenorphine)
d. Concomitant use of adjunctive medications.
As a result they were not able to identify a
standard treatment regimen. They concluded
that the use of an opioid antagonist, to induce
withdrawal, in combination with an α2-adrenergic
agonist to manage the signs and symptoms of
withdrawal appeared to be a feasible approach
to the management of opiate withdrawal. The
withdrawal syndrome tended to occur earlier and
was more severe than that seen with clonidine 
or lofexidine alone. However, it resolved more
quickly, which resulted in a higher number of
patients entering an antagonist maintenance
programme. The review was unable to evaluate
the long-term benefit of this finding.
Summary
Naloxone has been used, either alone or in
combination with naltrexone to bring about rapid
opiate withdrawal. Different dosage regimens
have been used and different concomitant
medications have been administered to lessen
the withdrawal symptoms. Data are too limited 
to evaluate the safety and effectiveness of any
dosage schedule.
Use of naloxone and/or naltrexone, in combination
with sedation or general anaesthesia has been
reported. There is insufficient information
regarding the efficacy and safety of this technique.
Furthermore, since this requires sedation and rapid
infusion of naloxone, this procedure may only be
considered for inpatient usage. (Note: Further
information on use of naloxone in managed
withdrawal can be found in the report “Use of
Lofexidine in the management of Opiate
Dependence Syndrome” at www.nacd.ie)
5.4 Use in Combination 
with Buprenorphine
A combination of buprenorphine and naloxone
(4:1 ratio) has been developed as a substitution
treatment in opioid dependence and this was
recently approved for use by the US Food and
Drug Administration (FDA, 2002). Results of
preliminary studies with this combination have
previously been presented (Teeling et al, 2002).
Among the pivotal studies that resulted in the US
authorisation of this combination (Suboxone®)
and the buprenorphine preparation (Subutex®)
was a double blind randomised placebo-
controlled trial which evaluated the safety 
and efficacy of 4 weeks’ treatment with either
Suboxone®, Subutex® or placebo in 323 
opiate-dependent subjects (McClellan, 2002).
Patients received daily doses of 16mg of either
preparation or placebo (n = 105, 109, 109
respectively) for 4 weeks (Suboxone® company
report, 2002). Results showed significant
improvement in the treated groups compared 
to the placebo group, in terms of negative 
urines and opiate craving – the primary efficacy
variables. In addition, the treated groups showed
greater improvements in their self-reported and
clinicians’ global impression scores, compared
with the placebo group.
The most frequently reported adverse events
during the 4 weeks related to opiate withdrawal
symptoms. There were no significant differences
between the 3 groups in respect of liver or kidney
function tests.
This study was carried into a 1-year open label
safety study, which showed that, following 6
months of treatment, 50% of urine samples were
negative for opiates. Safety profile with longer
treatment revealed no unexpected toxicity. The
commonest treatment-related effects were
headache and constipation.
As Suboxone® has just recently been authorised
for use in the US, there are no published studies
available of use of this combination in clinical
practice to date.
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Subutex® and Suboxone® are the first opiate
medications to be licensed for prescribing in 
an office setting in the USA, under the Drug
Addiction Treatment Act, 2000 (FDA, 2002). 
This is because it is felt that they pose less risk 
of dependence. It also provides patients in the
USA with greater access to treatment.
Subutex® is authorised for use in opiate
dependence in Ireland, but there is no
combination of buprenorphine and naloxone
currently authorised.
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Illicit opiate use has been a public health problem
in Ireland since the early 1980s and drug-related
deaths are an important cause of premature
mortality. Methadone maintenance has been
available since the 1990s and is the mainstay of
treatment in Ireland. A review was previously
undertaken on the effectiveness of buprenorphine
as an intervention in the management of opiate
dependence syndrome. The current review
evaluated the effectiveness of naloxone in the
management of opiate dependence. A systematic
review of all available data, retrieved from the
published literature, was undertaken. Contact was
made with experts who have experience in the
use of naloxone in order to evaluate the practical
issues associated with its usage.
The results of the review may be summarised as
follows:
1. Naloxone has been used for many years as 
an emergency room treatment for suspected
opiate overdose. However, few controlled
studies, involving different dosage schedules,
have been identified in this setting. Results
showed that naloxone was effective in
reversing the effects of opioid overdose but
was associated with serious adverse events 
in a small number of treated patients.
2. Observational studies, evaluating the use 
of naloxone by trained ambulance personnel
in the pre-hospital setting have shown that
naloxone was effective in reversing the signs
and symptoms of opiate overdose and in
reducing the need for subsequent hospital
admission. Different dosage regimens and
routes of administration were used and 
long-term follow-up data are insufficient to
determine the occurrence of long-term
sequelae.
3. No controlled studies have been undertaken
to evaluate the effectiveness of take-home
naloxone (for peer administration) in
prevention or reduction of fatal opiate
overdose. Data from case reports (involving
less than 100 usages) are insufficient data to
judge whether the addition of naloxone has
improved survival rates compared with use of
basic first aid techniques (such as assisted
breathing and calling for an ambulance) alone.
4. If a take-home naloxone programme were to
be considered, in the absence of data from
controlled trials, there are several key issues
that need to be addressed before such a
scheme could be initiated. These include 1)
clarification of the legal responsibilities of all
personnel involved, including prescriber,
pharmacist, distributor, patient and
administrator of the drug 2) identification of
the proper location(s) of such a programme in
order to reach users most at risk of overdose
3) provision of adequate training of the staff
involved in running the programme 4)
provision of adequate training for the drug
users (and their peers) involved in the
programme and 5) provision of adequate
monitoring of the programme to record
outcome data of use and to ensure that
used/post-expired supplies are replaced.
5. Naloxone has been used in combination with
other agents in the management of opiate
withdrawal. Data are too heterogeneous to
identify an optimal dosing regimen. It appears
that the withdrawal syndrome occurs earlier, 
is more severe and resolves more quickly with
naloxone. Long-term benefits of rapid opiate
withdrawal have not been studied.
6. Naloxone has been combined with
buprenorphine for sublingual use, with 
the aim of reducing the abuse potential of
buprenorphine. Results from clinical trials
show that this combination appears to be 
as effective as buprenorphine alone as a
maintenance/substitution treatment for 
opiate dependence. There is no published
experience of use of this combination in
clinical practice to date.
In conclusion, this review suggests that naloxone
may be regarded as a useful additional treatment
option in the overall management of opiate
dependence. However, several key issues would
need to be addressed before a programme of
take-home naloxone for emergency use could 
be implemented in practice.
Summary and Conclusions
Chapter 6
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I. General Questions
1. Have you experience of using naloxone in
your practice/previous working experience 
for this indication?
Yes/No (delete as appropriate)
2. If yes to 1, please outline 
a. The benefits of such a scheme to the
patients involved
b. The problems of such use (clinical, practical),
excluding the medico-legal aspects
c. The type of personnel who were involved 
in administering naloxone (e.g. community
healthcare workers only/relative or
friends/others)
3. What, in your opinion, is the biggest advantage
of having naloxone available in the community
for the management of opiate overdose
For the patient?
For the community?
4. What, in your opinion, are the disadvantages
of making naloxone available in the community
for the management of opiate overdose
For the patient?
For the community?
Questions on Naloxone Use in the 
Management of Opiate Overdose
Appendix I
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II. Clinical And Practical Issues
1. Because of its short duration of action, 
is naloxone rescue suitable for all situations –
(tick for yes)
a. Heroin alone 
b. Methadone alone 
c. Polydrug OD suspected 
d. Overdose due to unknown drug/drugs 
e. Other (please specify) 
2. If no to any listed in 1, please give reasons why
3. If no to any listed in 1, how do you think such
use can be prevented in the community?
(please specify)
4. What are the precautions that need to be
taken when administering naloxone?
5. What are the basic requirements for
instruction for correct use, before making
naloxone available in the community for
a. Patient (ultimate recipient)?
b. Relative/friend who may be required to
administer naloxone?
c. Paramedic/healthcare worker who may be
required to administer naloxone in the
community (e.g. ambulance personnel)?
6. In your opinion, should naloxone use in the
community be allowed to 
All who might come into contact with the
patient?
Yes/No (delete as appropriate)
Paramedics/healthcare workers only, who have
received basic training in the appropriate use
of naloxone?
Yes/No (delete as appropriate)
Please give reasons for your answer
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7. How could training for emergency use be
implemented into the community, in your
opinion?
For paramedics
For friends/relatives of heroin users
8. How could the practicalities of supply be
handled at community level? (e.g. prescription,
dispensing, storage precautions, expiry of
naloxone supplies) – tick for yes as appropriate
a. By setting up depots similar to needle
exchange centres 
b. Via the clinic/primary care setting for 
users, currently undergoing a treatment
programme 
c. By allowing dispensing without
prescription, by community pharmacists 
d. By allowing dispensing without
prescription, by designated community
pharmacists 
e. Other means (please specify) 
9. Should such supply be monitored in the
community by – tick for yes as appropriate
a. The treatment clinic? 
b. The provider of the supplies? 
c. Community workers such as drug 
workers or public health nurses? 
d. Community pharmacists? 
e. No monitoring necessary 
f. Monitoring not feasible 
Please add in any other points that you feel
are important for naloxone use as a rescue
medication in the community 
Signature and date 
End Of Questionnaire. Thank you!
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